Editorial Board
David Fisher
Massachusetts General Hospital, Harvard Medical School · United States
Editorial leadership for Journal of Dermatologic Research And Therapy ISSN 2471-2175
Research interests
- Melanocytes
- Pigmentation
- Melanoma
- Transcription
- Signaling
Biography
- David E. Fisher MD, PhD serves as Chair of the Dept of Dermatology at Mass General Hospital.
- His research focus has been on the MITF transcription factor, UV signaling events in skin, pathways of melanoma formation, and small molecule strategies for treatment of melanoma and skin diseases.
- Dr. David Fisher is a medical oncologist in Boston, Massachusetts and is affiliated with Massachusetts General Hospital.
- He received his medical degree from Weill Cornell Medical College of Cornell University and has been in practice for more than 20 years.
- Dr. Fisher accepts several types of health insurance, listed below. He is one of 131 doctors at Massachusetts General Hospital who specialize in Medical Oncology.
- Dr. Fisher received undergraduate degrees in Biology and Chemistry at Swarthmore College and Cello at the Curtis Institute of Music.
- He obtained his MD from Cornell Medical College and PhD from Rockefeller University, followed by clinical training in Internal Medicine at Mass General Hospital, and Adult and Pediatric Oncology at Dana Farber Cancer Institute and Children's Hospital, Harvard Medical School.
- He carried out postdoctoral training with Dr. Phillip Sharp at MIT.
- His research career focused on the role of transcription factors in melanocyte development and melanoma, particularly the MITF transcription factor.
- After leading a laboratory at Dana Farber for 15 years he became Chairman of Dermatology at Massachusetts General Hospital in 2008, where he also serves as Director of the Melanoma Program at MGH Cancer Center.
Considering JDRT for your work?
This journal is guided by David Fisher (Massachusetts General Hospital, Harvard Medical School) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.